KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Inventory: 2016-2025

Historic Inventory for Sarepta Therapeutics (SRPT) over the last 9 years, with Sep 2025 value amounting to $1.1 billion.

  • Sarepta Therapeutics' Inventory rose 90.34% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 90.34%. This contributed to the annual value of $750.0 million for FY2024, which is 132.29% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Inventory stood at $1.1 billion for Q3 2025, which was up 8.36% from $994.0 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Inventory ranged from a high of $1.1 billion in Q3 2025 and a low of $186.2 million during Q4 2021.
  • In the last 3 years, Sarepta Therapeutics' Inventory had a median value of $485.8 million in 2024 and averaged $562.2 million.
  • Per our database at Business Quant, Sarepta Therapeutics' Inventory declined by 23.32% in 2022 and then skyrocketed by 152.04% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Inventory (Quarterly) stood at $186.2 million in 2021, then climbed by 9.54% to $204.0 million in 2022, then surged by 58.29% to $322.9 million in 2023, then surged by 132.29% to $750.0 million in 2024, then soared by 90.34% to $1.1 billion in 2025.
  • Its Inventory stands at $1.1 billion for Q3 2025, versus $994.0 million for Q2 2025 and $941.4 million for Q1 2025.